Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties-Reference-Cited by-同舟云学术

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

Published:2017-05-23 Issue:32 Volume:8 Page:53053-53067
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Costa Federica¹,Vescovini Rosanna¹,Bolzoni Marina¹,Marchica Valentina¹,Storti Paola¹,Toscani Denise¹,Accardi Fabrizio¹²,Notarfranchi Laura¹²,Dalla Palma Benedetta¹²,Manferdini Cristina³,Manni Sabrina⁴,Todaro Giannalisa¹,Lisignoli Gina³,Piazza Francesco⁴,Aversa Franco¹²,Giuliani Nicola¹²

Affiliation:

1. Department of Medicine and Surgery, University of Parma, Parma, Italy

2. Hematology and BMT Center, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

3. Laboratory of Immunorheumatology and Tissue Regeneration, Istituto Ortopedico Rizzoli, Bologna, Italy

4. Department of Medicine, Hematology Branch, University of Padova and Venetian Institute of Molecular Medicine, Padova, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

2. Research and Analysis of Molecules such as CD28, CD45RA, CD45RO, CD38, HLA-DR, and CD57 on T Cells in Multiple Myeloma;Clinical Laboratory;2024

3. Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma;Clinical & Translational Immunology;2023-01

4. Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma;Clinical Infection in Practice;2023-01

5. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?;International Journal of Molecular Sciences;2022-12-14